Kelly Beck serves as Vice President, Investor Relations and Administration and Corporate Secretary of the Company. She has served as Ocugen’s Vice President, Investor Relations and Administration since July 2017. Prior to joining Ocugen, Ms. Beck worked at hrQ as Vice President and Managing Director from August 2016 June to 2017. Ms. Beck brings significant experience working with start up organizations and rapid growth companies, with the last 12 years focused in the life sciences industry. In her role at the Company, she is responsible for investor relations, communications, marketing, human resources, information technology and facilities. Ms. Beck has served in senior human resources and administrative leadership roles with PRA Health Sciences from February 2015 to August 2016, DrugDev (formerly CFS Clinical) from January 2011 to January 2015, Pennsylvania Bio, from August 2009 to May 2010, Tengion, Inc. from April 2005 to August 2009 and General Fiber Communications from April 2003 to April 2005. Ms. Beck obtained her MBA from Penn State University with a concentration in biotechnology and health industry management, M.S in Human Resource Development from Villanova University and her BS in Business Administration with a concentration in Accounting from Millersville University. She also holds SPHR, SHRM SCP and PMP certifications.
Kelly Beck is 43, she's been the Vice President、 Investor Relations and Administration and Corporate Secretary of Ocugen Inc since 2019. There are 15 older and 1 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
Kelly's mailing address filed with the SEC is C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN, PA, 19355.
Over the last 5 years, insiders at Ocugen Inc have traded over 18,069,176$ worth of Ocugen Inc stock and bought 1,511,356 units worth 684,830$ . The most active insiders traders include Shankar Musunuri、Junge Zhang、Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of 96,347$. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth 100,139$.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: